KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Inventory (2017 - 2025)

Novartis Ag (NVS) has disclosed Inventory for 9 consecutive years, with $6.3 billion as the latest value for Q4 2025.

  • Quarterly Inventory rose 9.54% to $6.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.3 billion through Dec 2025, up 9.54% year-over-year, with the annual reading at $6.3 billion for FY2025, 9.54% up from the prior year.
  • Inventory hit $6.3 billion in Q4 2025 for Novartis Ag, up from $5.7 billion in the prior quarter.
  • In the past five years, Inventory ranged from a high of $7.2 billion in Q4 2022 to a low of $5.7 billion in Q4 2024.
  • Historically, Inventory has averaged $6.3 billion across 5 years, with a median of $6.3 billion in 2025.
  • Biggest five-year swings in Inventory: fell 17.59% in 2023 and later increased 9.54% in 2025.
  • Year by year, Inventory stood at $6.7 billion in 2021, then increased by 7.64% to $7.2 billion in 2022, then decreased by 17.59% to $5.9 billion in 2023, then fell by 3.21% to $5.7 billion in 2024, then grew by 9.54% to $6.3 billion in 2025.
  • Business Quant data shows Inventory for NVS at $6.3 billion in Q4 2025, $5.7 billion in Q4 2024, and $5.9 billion in Q4 2023.